Elysia Alvarez

ORCID: 0000-0002-1615-2848
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Childhood Cancer Survivors' Quality of Life
  • Acute Lymphoblastic Leukemia research
  • Sarcoma Diagnosis and Treatment
  • Palliative Care and End-of-Life Issues
  • Lymphoma Diagnosis and Treatment
  • Adolescent and Pediatric Healthcare
  • Economic and Financial Impacts of Cancer
  • Ethics and Legal Issues in Pediatric Healthcare
  • Family Support in Illness
  • Bone Tumor Diagnosis and Treatments
  • Neutropenia and Cancer Infections
  • Family and Patient Care in Intensive Care Units
  • Tumors and Oncological Cases
  • Multiple and Secondary Primary Cancers
  • Healthcare Policy and Management
  • Testicular diseases and treatments
  • Management of metastatic bone disease
  • Cancer survivorship and care
  • Child and Adolescent Health
  • Neuroblastoma Research and Treatments
  • Cardiac tumors and thrombi
  • Soft tissue tumor case studies
  • Colorectal and Anal Carcinomas
  • Thermoregulation and physiological responses
  • Cutaneous lymphoproliferative disorders research

University of California, Davis
2018-2024

UC Davis Comprehensive Cancer Center
2024

Stanford Medicine
2016-2022

University of California Davis Medical Center
2020

Stanford University
2015-2018

University of Alabama at Birmingham
2017-2018

Adaptive Biotechnologies (United States)
2018

Palo Alto University
2017

Children's Hospital Colorado
2016

Community Health Center
2016

Many adult patients with cancer who know they are dying choose less intense care; additionally, high-intensity care is associated worse caregiver outcomes. Little known about intensity of end-of-life in children cancer.By using the California Office Statewide Health Planning and Development administrative database, we performed a population-based analysis aged 0 to 21 died between 2000 2011. Rates sociodemographic clinical factors previously-defined indicators were determined. The included...

10.1542/peds.2017-0671 article EN PEDIATRICS 2017-09-28
Elysia Alvarez Lisa M Force Rixing Xu Kelly Compton Dan Lu and 95 more Hannah Jacqueline Henrikson Jonathan Kocarnik James Harvey Alyssa Pennini Frances Dean Weijia Fu Martina T Vargas Theresa H.M. Keegan Hany Ariffin Ronald D. Barr Yana Arturovna Erdomaeva Sanjeeva Gunasekera Yetunde O. John-Akinola Tyler G. Ketterl Tezer Kutluk Marcio H. Malogolowkin Prashant Mathur Venkatraman Radhakrishnan Lynn A. G. Ries Carlos Rodríguez‐Galindo G. B. Sagoyan Iyad Sultan Behzad Abbasi Mohsen Abbasi‐Kangevari Zeinab Abbasi-Kangevari Hedayat Abbastabar Michael Abdelmasseh Sherief Abd‐Elsalam Amir Abdoli Haimanot Abebe Aidin Abedi Hassan Abidi Hassan Abolhassani Hiwa Abubaker Ali Eman Abu‐Gharbieh Basavaprabhu Achappa Juan Acuña Isaac Akinkunmi Adedeji Oyelola A. Adegboye Qorinah Estiningtyas Sakilah Adnani Shailesh M Advani Muhammad U. Afzal Mohamad Aghaie Meybodi Bahman Ahadinezhad Bright Opoku Ahinkorah Sajjad Ahmad Sepideh Ahmadi Muktar Beshir Ahmed Tarik A. Rashid Yusra Ahmed Salih Wajeeha Aiman Gizachew Taddesse Akalu Hanadi Al Hamad Fares Alahdab Abdulhadi A. AlAmodi Fahad Mashhour Alanezi Turki Alanzi Adugnaw Zeleke Alem Dejen Tsegaye Yosef Alemayehu Fadwa Alhalaiqa Robert Kaba Alhassan Saqib Ali Gianfranco Alicandro Vahid Alipour Syed Mohamed Aljunid Motasem Alkhayyat Sunitha Alluri Nihad A. Almasri Sadeq Ali Al‐Maweri Sami Almustanyir Rajaa Al‐Raddadi Nelson Alvis‐Guzmán Edward Kwabena Ameyaw GK Mini Hubert Amu Robert Ancuceanu Cătălina Liliana Andrei Tudorel Andrei Fereshteh Ansari Alireza Ansari-Moghaddam Davood Anvari Anayochukwu Edward Anyasodor Jalal Arabloo Morteza Arab‐Zozani Ayele Mamo Muhammad Arshad Judie Arulappan Armin Aryannejad Zatollah Asemi Mohammad Asghari Jafarabadi Mohammad Reza Atashzar Prince Atorkey Alok Atreya Sameh Attia

In estimating the global burden of cancer, adolescents and young adults with cancer are often overlooked, despite being a distinct subgroup unique epidemiology, clinical care needs, societal impact. Comprehensive estimates in (aged 15-39 years) lacking. To address this gap, we analysed results from Global Burden Diseases, Injuries, Risk Factors Study (GBD) 2019, focus on outcome disability-adjusted life-years (DALYs), to inform control measures adults.

10.1016/s1470-2045(21)00581-7 article EN cc-by The Lancet Oncology 2021-12-03

To identify the percentage of parents who define threshold for fever between 38.0°C and 38.3°C, which has not been reported previously, to describe parental attitudes toward antipyretic use.Thirteen-question survey study caregivers.Overall, 81% participants defined as <38.0°C, 0% correctly 19% >38.3°C. Twenty percent children brought clinic a chief complaint were never truly febrile. Ninety-three believed that high can cause brain damage. For comfortable-appearing child with fever, 89%...

10.1177/0009922812472252 article EN Clinical Pediatrics 2013-01-24

BACKGROUND Adolescents and young adults (AYAs) ages 15 to 39 years with cancer continue experience disparate survival outcomes compared their younger older counterparts. This may be caused in part by differential access specialized centers (SCCs), because treatment at SCCs has been associated improved overall survival. The authors examined social clinical factors AYA use of (defined as Children's Oncology Group‐designated or National Cancer Institute‐designated centers). METHODS A...

10.1002/cncr.30562 article EN Cancer 2017-02-27

Treatment refusal and abandonment are major causes of treatment failure for children with cancer in low- middle-income countries (LMICs), like Guatemala. This study identified risk factors described the intervention that decreased abandonment.This was a retrospective Guatemalan (0-18 years) treated at Unidad Nacional de Oncología Pediátrica (UNOP), 2001-2008, using Pediatric Oncology Network Database. to begin lapse 4 weeks or longer treatment. The impact medicina integral, multidisciplinary...

10.1002/pbc.26560 article EN Pediatric Blood & Cancer 2017-04-19

Cancer is the leading cause of nonaccidental death among adolescents and young adults (AYAs). High-intensity end-of-life care expensive may not be consistent with patient goals. However, intensity for AYA decedents cancer-especially effect received at specialty versus nonspecialty centers-remains understudied.We conducted a retrospective, population-based analysis California administrative discharge database that linked to certificates. The cohort included Californians age 15 39 years who...

10.1200/jop.2016.020586 article EN Journal of Oncology Practice 2017-08-22

Private health insurance is associated with improved outcomes in patients cancer. However, to the authors' knowledge, little known regarding impact of Patient Protection and Affordable Care Act Dependent Coverage Expansion (ACA-DCE), which extended private young adults (to age 26 years) beginning 2010, on status cancer.The current study was a retrospective, population-based analysis hospitalized adult oncology (aged 22-30 California during 2006 through 2014 (11,062 patients). Multivariable...

10.1002/cncr.30978 article EN Cancer 2017-09-22

BACKGROUND Studies of adolescent and young adult (AYA) oncology end‐of‐life care utilization are critical because cancer is the leading cause nonaccidental AYA death contributes significantly to health expenditures. This study was designed determine quantity disparities in inpatient last year life AYAs with cancer. METHODS The California Office Statewide Health Planning Development administrative discharge database, linked certificates, used perform a population‐based analysis patients aged...

10.1002/cncr.31233 article EN Cancer 2018-02-02

Sociodemographic and clinical factors associated with diagnostic delays in pediatric, adolescent, young adult cancers are poorly understood.

10.1002/pbc.30997 article EN Pediatric Blood & Cancer 2024-06-12

Intensity of end-of-life care receives much attention in oncology because concerns that high-intensity is inconsistent with patient goals, leads to worse caregiver outcomes, and expensive. Little known about such those undergoing allogeneic hematopoietic cell transplantation (HCT), a population at high risk for morbidity mortality.We conducted population-based analysis patients who died between 2000 2013, within 1 year an inpatient HCT using California administrative data. Previously...

10.1200/jco.2018.78.0957 article EN Journal of Clinical Oncology 2018-09-05

Background: People with sickle cell disease (SCD) have a life expectancy of <50 years, so understanding their end-of-life care is critical. Objective: We aimed to determine where individuals SCD were dying and patterns in the year preceding death highlight research priorities possible opportunities for intervention. Design: Using California Data Collection Program database (containing administrative data, vital records, Medicaid claims), we examined people who died between 2006 2015 (cases)...

10.1089/jpm.2018.0649 article EN Journal of Palliative Medicine 2019-08-07

Summary Little is known about the incidence of late effects following non‐Hodgkin lymphoma (NHL) among adolescent and young adult (AYA, 15–39 years) survivors. Using data from California Cancer Registry linked to hospital discharge, we estimated cumulative at 10 years AYAs diagnosed with NHL during 1996–2012, who survived ≥2 years. Cox proportional‐hazards models were used investigate influence sociodemographic clinical factors on occurrence effects. Of 4392 HIV‐uninfected patients, highest...

10.1111/bjh.16539 article EN British Journal of Haematology 2020-02-20

Abstract Background Despite efforts to increase participation of adolescents and young adults (AYAs; 15–39 years) in cancer clinical trials (CTs), enrollment remains very low. Even when provided access CTs, AYAs are less likely participate than children older adults. A better understanding oncologist‐ AYA survivor‐reported barriers, facilitators, potential areas for CT improvement is needed. Procedures From December 2019 August 2020, we conducted 43 semi‐structured interviews with...

10.1002/pbc.29479 article EN Pediatric Blood & Cancer 2021-12-16

We examined the use of Pediatric Cancer Specialty Centers (PCSCs) over time and length stay (LOS) in pediatric oncology patients with a diagnosis febrile neutropenia. PCSCs were defined as Children's Oncology Group California Services designated centers. performed retrospective analysis on all discharges (0 to 18) neutropenia (1983 2011) using private Office Statewide Health Planning Development database. influence age, sex, race/ethnicity, payer, income, distance, tumor type, complications...

10.1097/mph.0000000000000716 article EN Journal of Pediatric Hematology/Oncology 2016-12-02

Abstract Purpose The ideal local treatment modality for pelvic and sacral Ewing sarcoma (EWS) is controversial. Methods We present the data from American College of Surgeon's National Cancer Database (NCDB) Institute's Surveillance, Epidemiology End Result (SEER) database to investigate impact modalities on survival nonmetastatic sarcoma. Local includes “surgery,” “radiation,” a combination “surgery radiation.” Results A total 235 cases SEER 285 NCDB were analyzed. Patients with “localized”...

10.1002/jso.26922 article EN Journal of Surgical Oncology 2022-05-18

In this population-based evaluation of adolescents and young adults (AYA) acute lymphoblastic leukemia (ALL), we describe patterns care (POC) outcomes regarding hematopoietic cell transplantation (HCT) in first complete remission (CR1). Data were abstracted from the 2013 United States Surveillance, Epidemiology, End Results POC study; newly diagnosed AYA ALL included. Multivariable logistic regression evaluated associations with HCT CR1; Cox proportional hazards survival associations. Of 399...

10.1089/jayao.2018.0140 article EN Journal of Adolescent and Young Adult Oncology 2019-01-18

Primary sarcomas originating from the bones of hand and wrist are rare but carry a significant burden morbidity.National Cancer Institute's Surveillance, Epidemiology End Result database 1975 to 2017 was queried report incidence survival data in 237 patients United States. Kaplan-Meier Cox regression were used determine prognostic factors affecting survival. χ2 test assess correlation.Incidence sarcoma 0.017 per 100 000 persons has not significantly changed since (p > 0.05). Disease-specific...

10.1002/jso.26659 article EN Journal of Surgical Oncology 2021-08-25

Background: Soft tissue sarcomas (STS) are a heterogeneous group of tumors whose management benefits from multidisciplinary therapeutic approach. Published data suggest that cancer treatment at specialized center (SCC) can improve survival in other cancers. Therefore, we examined the impact location on children and adolescents young adults (AYAs) with STS. Methods: We performed population-based analysis AYAs hospitalized within 1 year diagnosis first primary STS (2000–2014) using California...

10.1089/jayao.2021.0110 article EN Journal of Adolescent and Young Adult Oncology 2021-12-15
Coming Soon ...